Advertiser / Brand
HERMES ARZNEIMITTEL vs Revolution Beauty
Structured technology and market comparison · 2026
Direct Feature Comparison
HERMES ARZNEIMITTEL · vs · Revolution BeautyGerman OTC pharmaceuticals and consumer health brand company.
Public beauty brand selling makeup, skincare and haircare products.
Analyze all overlapping signals and tech stacks for HERMES ARZNEIMITTEL and Revolution Beauty
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between HERMES ARZNEIMITTEL and Revolution Beauty?
When comparing HERMES ARZNEIMITTEL and Revolution Beauty, both platforms operate within the Advertiser / Brand ecosystem. HERMES ARZNEIMITTEL is positioned as German OTC pharmaceuticals and consumer health brand company, whereas Revolution Beauty focuses on Public beauty brand selling makeup, skincare and haircare products. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to HERMES ARZNEIMITTEL and Revolution Beauty?
When evaluating HERMES ARZNEIMITTEL and Revolution Beauty, enterprise buyers also consider other platforms in Advertiser / Brand. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of HERMES ARZNEIMITTEL and Revolution Beauty compare?
HERMES ARZNEIMITTEL is headquartered in DE (founded in 1907) with 50–200 employees. Revolution Beauty is based in GB (founded in 2014) with 201–500 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: HERMES ARZNEIMITTEL vs Revolution Beauty
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
HERMES ARZNEIMITTEL
Recent Signals
- ·HorizontAgency & Consultancy
Havas Retains Hermes Arzneimittel Media Account
Havas Media’s Frankfurt office has been confirmed as Hermes Arzneimittel’s media agency after winning a multi-stage pitch. From 2027 the agency will take responsibility for the full media budget — including digital activities — in an assignment valued in the mid single-digit million euro range. Havas, which has served Hermes since 2013, will assume additional brand duties that, together with digital responsibilities, will double the media volume it manages for the client. Hermes’ brands cited include Antibrumm (Anti Brumm), Compeed (blister plasters), Algorvir (algovir), Biolectra Magnesium, Betaisodona and doc. The win was reported by Horizont on 17 August 2026.
- Havas Media (Frankfurt) won Hermes Arzneimittel’s full media account following a multi-stage pitch.
- Havas will assume responsibility for the account from 2027, including digital activities.
- The account is valued in the mid single-digit million euro range.
Revolution Beauty
Recent Signals
- ·SEC APIfinancials
8-K Financial Filing Analysis for Revolution Beauty (2026-08-19)
On August 17, 2026, the Compensation Committee of Revelation Biosciences, Inc. approved material restricted stock grants to executive leadership under its Amended and Restated 2021 Equity Incentive Plan. Chief Executive Officer James Rolke received 208,076 restricted shares, and Chief Financial Officer Chester S. Zygmont, III was granted 208,073 restricted shares. The equity awards are structured to vest across four equal 25% tranches linked to either reaching market capitalization hurdles of $30 million, $60 million, $90 million, and $120 million for 20 consecutive trading days, or time-based vesting at the two-year and four-year marks. The package aligns executive compensation with aggressive market valuation targets while providing retention security.
- CEO James Rolke and CFO Chester S. Zygmont, III were granted 208,076 and 208,073 restricted shares, respectively, under the 2021 Equity Incentive Plan.
- Awards vest in four equal 25% tranches upon reaching market capitalization thresholds of $30M, $60M, $90M, and $120M sustained over 20 consecutive trading days, or alternatively at 2-year (first two tranches) and 4-year (final two tranches) time intervals.
- Grants include standard accelerated vesting protections upon a Change in Control or qualified involuntary termination events.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners HERMES ARZNEIMITTEL and Revolution Beauty share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks